ING Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20M | Buy |
32,086
+895
| +3% | +$609K | 0.1% | 163 |
|
|
2026
Q1 | $24.1M | Sell |
31,191
-25,406
| -45% | -$19.5M | 0.15% | 117 |
|
|
2025
Q4 | $43.7M | Sell |
56,597
-52,280
| -48% | -$35.5M | 0.26% | 75 |
|
|
2025
Q3 | $61.2M | Buy |
108,877
+62,749
| +136% | +$35.5M | 0.33% | 56 |
|
|
2025
Q2 | $24.2M | Buy |
46,128
+24,797
| +116% | +$13.8M | 0.15% | 111 |
|
|
2025
Q1 | $13.5M | Sell |
21,331
-7,754
| -27% | -$5.33M | 0.09% | 139 |
|
|
2024
Q4 | $20.7M | Buy |
29,085
+7,324
| +34% | +$6.15M | 0.14% | 114 |
|
|
2024
Q3 | $22.9M | Buy |
21,761
+16,701
| +330% | +$18.6M | 0.13% | 120 |
|
|
2024
Q2 | $5.32M | Sell |
5,060
-22,247
| -81% | -$21.6M | 0.03% | 313 |
|
|
2024
Q1 | $26.3M | Sell |
27,307
-1,004
| -4% | -$955K | 0.18% | 102 |
|
|
2023
Q4 | $24.9M | Sell |
28,311
-7,484
| -21% | -$6.16M | 0.2% | 104 |
|
|
2023
Q3 | $29.5M | Buy |
35,795
+3,052
| +9% | +$2.4M | 0.26% | 82 |
|
|
2023
Q2 | $23.5M | Sell |
32,743
-91
| -0.3% | -$70.2K | 0.18% | 108 |
|
|
2023
Q1 | $27M | Buy |
32,834
+5,151
| +19% | +$3.88M | 0.26% | 79 |
|
|
2022
Q4 | $20M | Buy |
+27,683
| New | +$20.4M | 0.2% | 97 |
|
|
2022
Q3 | – | Sell |
-26,631
| Closed | -$15.7M | – | 517 |
|
|
2022
Q2 | $15.7M | Sell |
26,631
-27,500
| -51% | -$17.9M | 0.18% | 97 |
|
|
2022
Q1 | $37.8M | Buy |
54,131
+4,841
| +10% | +$3.06M | 0.38% | 58 |
|
|
2021
Q4 | $31.1M | Buy |
49,290
+38,616
| +362% | +$23.7M | 0.28% | 74 |
|
|
2021
Q3 | $6.46M | Buy |
10,674
+229
| +2% | +$142K | 0.08% | 157 |
|
|
2021
Q2 | $5.83M | Buy |
+10,445
| New | +$5.29M | 0.09% | 143 |
|
|
2021
Q1 | – | Sell |
-6,955
| Closed | -$3.36M | – | 545 |
|
|
2020
Q4 | $3.36M | Buy |
6,955
+4,641
| +201% | +$2.51M | 0.08% | 174 |
|
|
2020
Q3 | $1.29M | Buy |
2,314
+1,461
| +171% | +$886K | 0.05% | 169 |
|
|
2020
Q2 | $532K | Sell |
853
-609
| -42% | -$346K | 0.02% | 168 |
|
|
2020
Q1 | $714K | Buy |
+1,462
| New | +$603K | 0.03% | 221 |
|
|
2019
Q4 | – | Sell |
-4,988
| Closed | -$1.38M | – | 523 |
|
|
2019
Q3 | $1.38M | Sell |
4,988
-22,754
| -82% | -$6.73M | 0.04% | 255 |
|
|
2019
Q2 | $8.68M | Buy |
+27,742
| New | +$9.24M | 0.15% | 105 |
|
|
2019
Q1 | – | Sell |
-20,115
| Closed | -$7.51M | – | 803 |
|
|
2018
Q4 | $7.51M | Buy |
20,115
+16,395
| +441% | +$6M | 0.16% | 97 |
|
|
2018
Q3 | $1.5M | Buy |
+3,720
| New | +$1.42M | 0.03% | 282 |
|
|
2018
Q2 | – | Sell |
-8,142
| Closed | -$2.8M | – | 830 |
|
|
2018
Q1 | $2.8M | Buy |
+8,142
| New | +$2.83M | 0.05% | 183 |
|
|
2017
Q4 | – | Sell |
-13,470
| Closed | -$6.02M | – | 871 |
|
|
2017
Q3 | $6.02M | Buy |
+13,470
| New | +$6.41M | 0.12% | 133 |
|
|
2017
Q2 | – | Sell |
-12,250
| Closed | -$4.75M | – | 898 |
|
|
2017
Q1 | $4.75M | Buy |
+12,250
| New | +$4.54M | 0.09% | 153 |
|
|
2015
Q2 | – | Sell |
-3,734
| Closed | -$1.69M | – | 707 |
|
|
2015
Q1 | $1.69M | Buy |
3,734
+15
| +0.4% | +$6.36K | 0.01% | 531 |
|
|
2014
Q4 | $1.52M | Buy |
3,719
+2,854
| +330% | +$1.12M | 0.01% | 517 |
|
|
2014
Q3 | $312K | Sell |
865
-171
| -17% | -$57.3K | ﹤0.01% | 610 |
|
|
2014
Q2 | $293K | Hold |
1,036
| – | – | ﹤0.01% | 614 |
|
|
2014
Q1 | $311K | Sell |
1,036
-228
| -18% | -$70.2K | ﹤0.01% | 634 |
|
|
2013
Q4 | $348K | Buy |
1,264
+8
| +0.6% | +$2.3K | ﹤0.01% | 615 |
|
|
2013
Q3 | $393K | Buy |
1,256
+151
| +14% | +$39.7K | ﹤0.01% | 633 |
|
|
2013
Q2 | $249K | Buy |
+1,105
| New | +$257K | ﹤0.01% | 630 |
|
Other funds holding REGN
ING Group's REGN Position: Q2 2026 in Review
ING Group increased its Regeneron Pharmaceuticals (REGN) stake by 2.9% in Q2 2026, buying an estimated $609K and bringing the position to 32,086 shares worth $20M. The position accounts for 0.1% of the portfolio, ranked #163.
ING Group first reported a position in REGN in Q2 2013 and has held it in 39 quarters since. The position peaked at $61.2M in Q3 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- ING Group held 32,086 shares of Regeneron Pharmaceuticals worth $20M as of Q2 2026.
- ING Group bought 895 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $609K.
- Regeneron Pharmaceuticals made up 0.1% of ING Group's portfolio in Q2 2026, its #163 holding.
- ING Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
- ING Group's Regeneron Pharmaceuticals position peaked at $61.2M in Q3 2025.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.